Program
azirkitug
In AbbVie's pipeline, CCR8
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AbbVie.
Furthest: phase 1, since Aug 12, 20211 company-led study, 1 open or runningNext primary completion: Jul 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 1since Aug 12, 2021 | Aug 12, 2021 | Jul 2027phase 1 · NCT05005403 |
- Named in AbbVie’s own pipeline as
Azirkitig (ABBV-514)
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2021First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05005403 · 694 planned · United States, Canada, Israel and more
Ahead
- Jul 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05005403
TargetBeta
“CCR8”the company's pipeline, read by Claude · source
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05005403Carcinoma, Non-Small-Cell Lung · United States, Canada, Israel and more | 1 | Recruiting | Jul 2027 | 694 |
How it is read
Names in the registry
- “Azirkitug”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.